Phosphocholine Adsorbent Matrix for CRP Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing elevated C-reactive protein (CRP) levels, particularly in patients at risk for cardiovascular disease, are inadequate in effectively lowering CRP levels, especially in cases of high CRP after a heart attack or in dialysis patients, and existing treatments have side effects or do not specifically target CRP removal from biological fluids.
Innovation Solution
The use of a pharmaceutical agent containing compounds that temporarily bind CRP, such as lipids, peptides, and phosphocholine derivatives, incorporated into an adsorbent matrix within a device for extracorporeal perfusion of blood plasma to remove CRP from biological fluids, thereby reducing cardiovascular risk factors and associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If extracorporeal perfusion through adsorbent matrix is used, then CRP removal efficiency is improved, but device complexity increases
Solution Approach 1:
The patent employs an adsorbent matrix with porous structure that contains phosphocholine groups. These porous materials provide high surface area for CRP binding while maintaining a relatively simple device configuration. The matrix material allows efficient CRP removal through adsorption without requiring complex mechanical or chemical systems.
Solution Approach 2:
The patent replaces complex mechanical CRP removal systems with a chemical adsorption-based approach. Instead of using mechanical filtration or complex separation devices, the invention uses phosphocholine-containing adsorbent materials that selectively bind CRP through molecular interactions, thereby simplifying the overall device architecture while maintaining high removal efficiency.
2Quantity of substance
If phosphocholine-containing adsorbent materials are used, then CRP binding capacity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent modifies the chemical parameters of adsorbent materials by incorporating phosphocholine groups or derivatives into the matrix structure. This chemical modification enhances CRP binding capacity through specific molecular interactions. The manufacturing process involves standard chemical functionalization techniques that, while adding some complexity, utilize well-established methods for introducing functional groups to polymer or silica-based matrices.
3Object-affected harmful factors
If CRP levels are reduced extracorporeally, then cardiovascular risk is reduced, but treatment cost increases
Solution Approach 1:
The patent employs disposable adsorbent cartridges or columns containing phosphocholine-functionalized materials that can be manufactured at relatively low cost using standard chemical modification techniques. These single-use or limited-use devices eliminate the need for expensive, complex, or reusable systems requiring sophisticated cleaning and regeneration protocols, thereby reducing overall treatment costs while effectively lowering cardiovascular risk through CRP removal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces CRP levels in biological fluids, providing prophylaxis and treatment for cardiovascular diseases, immune dysfunctions, and other conditions by temporarily binding CRP, which can be reused in patients, improving inflammatory parameters and reducing disease-related morbidity.
Implementation Method 1
extracorporeal perfusion of blood plasma from patients at risk for cardiovascular disease through a device, such as a column, which adsorbent matrix material containing lipids, peptides, polypeptides, phosphocholine (PC) or PC derivatives to remove C-reactive protein
Data Source
Figure 1~2
AI summary
The invention relates to a method for treating the risk of accumulating C-reactive protein (CRP) by performing an extracorporeal perfusion of blood plasma of patients presenting a risk of cardiovascular diseases or immune dysfunctions such as autoimmune diseases by means of an apparatus, e.g. a column, which contains absorbent matrix material including lipids, peptides, polypeptides, phosphocholine (PC), or PC derivatives, in order to eliminate C-reactive protein. The invention further relates to the use of compounds which have the property of at least temporarily binding CRP in order to eliminate CRP from a patient's biological liquids so as to prevent and/or treat autoimmune diseases, cardiovascular diseases such as myocardial infarction, stroke, diabetes, rheumatism, and renal insufficiency.